FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer

被引：0
|
作者：
Cuilan Sun
Weiwei Gao
Jiatao Liu
Hao Cheng
Jiqing Hao
机构：
[1] The First Affiliated Hospital of Anhui Medical University,Department of Oncology
[2] the First Affiliated Hospital of Anhui Medical University,Department of Pharmacy
来源：
Respiratory Research | / 21卷
关键词：
Fibrinogen-like-protein 1; Epidermal growth factor receptor; Non-small cell lung cancer; Gefitinib resistance; Apoptosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Gefitinib (Iressa) trials in non-small cell lung cancer
    Johnson, DH
    LUNG CANCER, 2003, 41 : S23 - S28
  • [42] Gefitinib: an "orphan" drug for non-small cell lung cancer
    Ziogas, Dimitrios C.
    Liontos, Michalis
    Kyriazoglou, Anastasios
    Tsironis, Georgios
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (11): : 899 - 906
  • [43] Gefitinib (Iressa) for advanced non-small cell lung cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2002, 44 (1138): : 77 - 78
  • [44] Safety of gefitinib in non-small cell lung cancer treatment
    Hsiue, Emily Han-Chung
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (07) : 993 - 1000
  • [45] ELK1/MTOR/S6K1 Pathway Contributes to Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer
    Zhao, Lei
    Wang, Yifang
    Sun, Xin
    Zhang, Xiujuan
    Simone, Nicole
    He, Jun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (04)
  • [46] PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway
    Mei-sa Wang
    Qiu-shuang Han
    Zhi-rong Jia
    Chuan-sheng Chen
    Chen Qiao
    Qian-qian Liu
    Ya-meng Zhang
    Kai-wei Wang
    Jie Wang
    Kang Xiao
    Xuan-sheng Ding
    Acta Pharmacologica Sinica, 2022, 43 : 167 - 176
  • [47] Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
    Karachaliou, Niki
    Codony-Servat, Jordi
    Paulina Bracht, Jillian Wilhelmina
    Ito, Masaoki
    Filipska, Martyna
    Pedraz, Carlos
    Chaib, Imane
    Bertran-Alamillo, Jordi
    Felipe Cardona, Andres
    Angel Molina, Miguel
    Rosell, Rafael
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (10) : 1019 - 1028
  • [48] STUDY OF MECHANISM OF REVERSE OF COX-2 INHIBITOR CELECOXIB ON ACQUIRED RESISTANCE TO GEFITINIB IN NON-SMALL CELL LUNG CANCER
    Deng, Q-F
    Su, B.
    Zhao, Y-M
    Tang, L.
    Zhang, J.
    Xu, J-F
    Zhou, C-C
    RESPIROLOGY, 2014, 19 : 37 - 37
  • [49] PPARα agonist fenofibrate relieves acquired resistance to gefitinib in non-small cell lung cancer by promoting apoptosis via PPARα/AMPK/AKT/FoxO1 pathway
    Wang, Mei-sa
    Han, Qiu-shuang
    Jia, Zhi-rong
    Chen, Chuan-sheng
    Qiao, Chen
    Liu, Qian-qian
    Zhang, Ya-meng
    Wang, Kai-wei
    Wang, Jie
    Xiao, Kang
    Ding, Xuan-sheng
    ACTA PHARMACOLOGICA SINICA, 2022, 43 (01) : 167 - 176
  • [50] The Molecular Mechanism of Circular RNA Molecule CircSETD3 in Gefitinib Acquired Resistance in Non-Small Cell Lung Cancer
    Su, Jing
    Zhao, J.
    Zhang, Ning
    Xiang, B.
    Zhi, Xuejun
    Huo, Y.
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 84 (05) : 1279 - 1287
12345